Thereafter, GLP-1 analogs have been increasingly studied as a noninvasive strategy for weight reduction, and they transitioned from diabetes-only therapies to weight management with the approval of once-daily liraglutide prior to weekly semaglutide formulation in 2021. In essence, GLP-1 receptor agonists have emerged as a promising drug for long-lasting weight reduction and blood glucose control for patients with or without type 2 diabetes mellitus, surpassing traditional methods such as lifestyle changes and bariatric surgery. Here, GCG is linked to type 2 diabetes mellitus.